XML 16 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Total revenue $ 51,240 $ 26,425 $ 95,446 $ 42,942
Operating costs and expenses        
Cost of sales 298 136 536 194
Total operating costs and expenses 112,937 97,710 226,934 178,656
Loss from operations (61,697) (71,285) (131,488) (135,714)
Other income (expense), net        
Interest and investment income, net 3,155 1,153 5,469 2,040
Change in fair value of related-party convertible note     (332,589) (41,413)
Change in fair value of warrant liabilities (44,190) 3,889 (339,603) 3,441
Interest expense related to revenue interest liability (17,192) (13,405) (31,063) (26,939)
Change in fair value of derivative liabilities (692) 1,931 416 7,509
Other income (expense), net 242 (278) (5,675) (319)
Total other expense, net (168,693) (21,020) (731,690) (86,491)
Loss before income taxes and noncontrolling interest (230,390) (92,305) (863,178) (222,205)
Income tax expense 0 (269) (9) (35)
Net loss (230,390) (92,574) (863,187) (222,240)
Net loss attributable to noncontrolling interests, net of tax (12) (19) (27) (39)
Net loss attributable to ImmunityBio common stockholders $ (230,378) $ (92,555) $ (863,160) $ (222,201)
Net loss per ImmunityBio common share – basic (in dollars per share) $ (0.22) $ (0.10) $ (0.83) $ (0.26)
Net loss per ImmunityBio common share - diluted (in dollars per share) $ (0.22) $ (0.10) $ (0.83) $ (0.26)
Weighted-average number of common shares used in computing net loss per share – basic (in shares) 1,050,070 888,216 1,038,536 870,786
Weighted-average number of common shares used in computing net loss per share – diluted (in shares) 1,050,070 888,216 1,038,536 870,786
Non-related Party        
Operating costs and expenses        
Research and development $ 57,690 $ 52,430 $ 122,460 $ 98,406
Selling, general and administrative 50,626 41,862 95,087 73,839
Other income (expense), net        
Interest expense (20) (5) (54) (23)
Related-Party        
Operating costs and expenses        
Research and development 3,126 2,806 6,345 5,064
Selling, general and administrative 1,197 476 2,506 1,153
Other income (expense), net        
Change in fair value of related-party convertible note (95,964) 1,169 (332,589) (41,413)
Interest expense (14,032) (15,474) (28,591) (30,787)
Product revenue, net        
Total revenue 50,672 26,421 94,839 42,930
Other revenues        
Total revenue $ 568 $ 4 $ 607 $ 12